ImmunityBio (IBRX) is trading higher Friday, April 17, 2026, as investors focus on the company’s latest disclosed commercial traction for ANKTIVA. The company recently posted preliminary Q1 2026 net product revenue of approximately $44.2 million, a record level for the business and a 168% increase from Q1 2025, reinforcing the narrative that the launch is scaling quarter-to-quarter. (immunitybio.com)

After a volatile stretch tied to regulatory messaging risk, the revenue print is being treated as a concrete datapoint on underlying demand. The stock had been hit on March 24, 2026 after the FDA flagged misleading promotional statements related to ANKTIVA, raising uncertainty about marketing practices even as the product remains commercially available. Friday’s move looks like a normalization trade as attention rotates back to prescriptions, reimbursement flow-through, and repeat ordering trends implied by sequential revenue growth. (apnews.com)

Near term, traders will likely focus on (1) confirmation of final Q1 financials versus preliminary figures, (2) updates on compliance actions tied to the FDA’s promotional concerns, and (3) whether commercial momentum continues through Q2 as the company expands its treatment footprint within the approved bladder-cancer setting. With the stock still sensitive to event risk, incremental operational disclosures—sales trajectory, channel inventory, and cash runway—could drive outsized moves in either direction.